In Silico Molecular Modelling And Docking Studies On Leukocidin LUKD In Staphylococcus Aureus | 4668
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

In silico molecular modelling and docking studies on leukocidin LUKD in Staphylococcus aureus

3rd World Congress on Biotechnology

Nidhina N, Manibharathi P, Nilavazhagan A, Swetha MP and Muthukumar SP

Posters: Agrotechnol

DOI: 10.4172/2155-952X.S1.020

Methicillin Resisistant Staphylococcus aureus (MRSA) infection is one of the most prevalent infection among the bacterial infections in animals as well as humans and are resistant to most of the potential antibiotics. The existing drugs are not sufficient to control and cure the infection. Panton Valentine Leukocidin (PVL), a β-pore forming cytotoxin, of prophage origin that helps MRSA to obtain the nutrient from host cell by oozing out the cell contents, increases its virulence. It targets phagocytes, especially polymorphonuclear neutrophils (PMNs), and also causes necrotising pneumonia. In silico docking provide a platform to study the interaction between the antimicrobial compounds and PVL. But no 3D molecular structure is available for PVL so far. Considering the above, the present study is focused to model a template for the protein and to find out the potential inhibitor for the PVL by interacting the available antibacterial compounds with the predicted active sites. We obtained γ-hemolysin as the template for PVL with 90% querry coverage and 77% identity through BLAST. The active sites are predicted by Q-Site Finder and are docked with existing antibacterial compounds using ArgusLab. Based on docking energy and hydrogen bond interaction, diathymosulfone, myrophine, andrimid, beclobrate and probucol are identified as best antibacterial compounds to be used as drugs against PVL containing MRSA.